전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved179 programs
ADCLimited DatastalePfizerPhase 3

INO (Inotuzumab ozogamicin, Inotuzumab ozogamicin (INO))

B-Cell Acute Lymphoblastic Leukaemia · B-Cell Acute Lymphoblastic Leukaemia

#B-CellAcuteLymphoblasticLeukaemi#ADC#Phase3#antibody-drug-conjugate#Pfizer
Trials 1Status Recruiting
CGTLimited DatastaleShanghai JW Therapeutics Co., L…Phase 1

JWCAR239 (JWCAR239)

B-Cell Non-Hodgkin Lymphoma; Large B Cell Diffuse Lymphoma · B-Cell Non-Hodgkin Lymphoma

#B-CellNon-HodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleNanjing Legend Biotech Co.Phase 1

LUCAR-20SP cells (LUCAR-20SP cells)

Relapsed B-cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleADC TherapeuticsPhase 1

durvalumab (Imfinzi, Loncastuximab Tesirine and Durvalumab)

Diffuse Large B-Cell Lymphoma; Mantle Cell Lymphoma · Diffuse Large B-Cell Lymphoma

#DiffuseLargeB-CellLymphoma#Antibody#Phase1#monoclonal-antibody#MantleCellLymphoma+1
Trials 1Status Discontinued
CGTLimited DatastaleMiltenyi Biomedicine GmbHPhase 2

MB-CART20.1 (MB-CART20.1)

Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleTechnische Universität DresdenPhase 1

BCMA directed CAR T-cells (MDC-CAR-BCMA001, MDC-CAR-BCMA001 (BCMA directed CAR T-cells))

Neoplasms; Relapsed Diffuse Large B-cell Lymphoma (DLBCL) · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
CGTLimited DatastaleLeman Biotech Co., Ltd.Phase 1

Metabolically Armed CD19 CAR-T cells (Metabolically Armed CD19 CAR-T cells)

Diffuse Large B-cell Lymphoma · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleLiqun ZouPhase 1

Modified anti-CD19 CAR T cells (Modified anti-CD19 CAR T cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 2

Nanobody-Based CD19/CD22 Tandem Dual CAR-T (Nanobody-Based CD19/CD22 Tandem Dual CAR-T)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
CGTLimited DatastaleTimmune Biotech Inc.Phase 1

Novel CAR-T (Novel CAR-T)

B-cell Non Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma

#B-cellNonHodgkinLymphoma#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastaleM.D. Anderson Cancer CenterPhase 2

ONC-PluReceptor NK cells (ONC-PluReceptor NK cells)

Recurrent B-Cell Non-Hodgkin Lymphoma; Refractory B-cell Non-Hodgkin Lymphoma · FRα

#FR#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleRochePhase 1

G (Obinutuzumab, Obinutuzumab (G))

B-Cell Lymphoma; Non-Hodgkin Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#Antibody#Phase1#monoclonal-antibody#Non-HodgkinLymphoma+1
Trials 1Status Active
CGTLimited DatastalePinze Lifetechnology Co. Ltd.Phase 1

PZ01 CAR-T cells (PZ01 CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma · B-cell Acute Lymphoblastic Leukemia

#B-cellAcuteLymphoblasticLeukemia#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Active
CGTLimited DatastalePell Bio-Med Technology Co., Lt…Preclinical

Pell's lentiviral-based gene-edited immune cell therapy (Pell's lentiviral-based gene-edited immune cell therapy)

Diffuse Large B Cell Lymphoma; Large B-cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Preclinical#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
CGTLimited DatastaleEden BioCell Ltd.Phase 1

RPM CD19-mbIL15-CAR-T cells (RPM CD19-mbIL15-CAR-T cells)

B-cell Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma, Relapsed · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Discontinued
AntibodyLimited DatastaleUniversity of Alabama at Birmin…Phase 1

Retifanlimab, INCAGN02385, INCAGN02390 (Retifanlimab, INCAGN02385, INCAGN02390)

Diffuse Large B Cell Lymphoma; Lymphoma, B-Cell · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#Antibody#Phase1#monoclonal-antibody#Lymphoma+2
Trials 1Status Discontinued

8 / 9 pages

← PreviousNext →